Human medicines European public assessment report (EPAR): Eylea, aflibercept, Wet Macular Degeneration;Macular Edema;Diabetes Complications, Date of authorisation: 21/11/2012, Revision: 30, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Chloroprocaine hydrochloride, decision type: , therapeutic area: , PIP number: P/0334/2022

Human medicines European public assessment report (EPAR): Neparvis, sacubitril,valsartan, Heart Failure, Date of authorisation: 26/05/2016, Revision: 18, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Otezla,apremilast, decision type: , therapeutic area: , PIP number: P/0352/2022

Opinion/decision on a Paediatric investigation plan (PIP): Otezla,apremilast, decision type: , therapeutic area: , PIP number: P/0353/2022

Human medicines European public assessment report (EPAR): Pandemic Influenza Vaccine H5N1 Baxter AG, pandemic influenza vaccine (H5N1) (whole virion, inactivated, prepared in cell culture), Influenza, Human;Immunization;Disease Outbreaks, Date of authorisation: 16/10/2009, Revision: 8, Status: Withdrawn

Opinion/decision on a Paediatric investigation plan (PIP): Bosulif,Bosutinib, decision type: , therapeutic area: , PIP number: P/0368/2021

Orphan designation: 2-[6-(6,7-Dimethoxyquinolin-3-yl)pyridin-3-yl]-N-[3-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-5-yl]acetamide (zeteletinib), Treatment of medullary thyroid carcinoma, 19/02/2021, Positive

Orphan designation: Entinostat, Treatment of Hodgkin's lymphoma, 10/06/2010, Positive

Orphan designation: Mixture of seven synthetic fragments consisting of p21 RAS peptides, Treatment of pancreatic cancer, 05/08/2011, Positive